Religare Enterprises Limited confirmed that its promoters have assured an infusion of ₹1,500 crore into the company to support seamless growth. This commitment was highlighted by the Board during the 42nd Annual General Meeting (AGM) held on September 24, 2026.

The meeting was conducted via video conferencing and other audio-visual means in compliance with Ministry of Corporate Affairs and SEBI circulars. Rajender Mohan Malla, Independent Director and Non-Executive Chairman, presided over the proceedings. The agenda included the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026.

Key resolutions and governance updates

Shareholders considered several ordinary and special resolutions during the virtual session. The re-designation of Arjun Lamba from Whole-time Director to Managing Director was a key item, passed as a special resolution. The company clarified that this change occurs at the same terms and conditions as his previous role. Additionally, Gurumurthy Ramanathan, who retired by rotation, offered himself for re-appointment.

Auditor reports and compliance

The Chairman informed members that the Auditors Report on both standalone and consolidated financial statements for FY26 contained no qualifications. However, the Secretarial Auditors Report for the same period did have certain qualifications, which were addressed in the Directors Report. The meeting noted the presence of statutory auditors J.C. Bhalla & Co. and secretarial auditors PI & Associates.

Voting results were facilitated through remote e-voting by KFin Technologies Limited. The scrutinizer, Ankush Agarwal of MAKS & Co., was appointed to ensure a fair voting process. Results are expected to be announced within two working days of the conclusion of the AGM.

What the numbers show

The explicit mention of the ₹1,500 crore capital infusion assurance serves as a significant signal of promoter confidence and liquidity support. While the specific timeline for this infusion was not detailed in the proceedings, the public commitment at the AGM suggests a strategic move to strengthen the balance sheet. This comes alongside the confirmation that statutory audit reports remained unqualified, indicating no major discrepancies in the reported financial figures for FY26.

Care Health Insurance Limited, a material subsidiary of Religare Enterprises , has allotted ₹100 crore worth of non-convertible debentures. The issuance was completed on September 18, 2026, at par value.

The securities carry a fixed coupon rate of 10% per annum and are structured as unsecured, subordinated, listed, taxable, rated, redeemable, non-cumulative, and non-convertible debentures. They qualify as 'Subordinated Debt' under IRDAI laws and SEBI NCS Regulations.

Issue Structure

The company issued 10,000 debentures, each with a face value of ₹1,00,000. The issue was conducted via private placement in dematerialized form. Key terms include:

Redemption and Interest Terms

The debentures mature on September 18, 2036, subject to a call option exercisable by the issuer at the end of five years and annually thereafter. Interest is paid annually and charged to the profit and loss account.

Payment of interest is conditional upon IRDAI regulations. The issuer is not liable to pay interest if prohibited by law or if payment would result in a net loss, increase existing net losses, or cause the solvency margin to fall below the Control Level of Solvency. Missed interest payments are non-cumulative and do not constitute an event of default, though dividend distribution to equity shareholders is restricted during such periods.